The akt kinase: molecular determinants of oncogenicity - PubMed (original) (raw)
The akt kinase: molecular determinants of oncogenicity
M Aoki et al. Proc Natl Acad Sci U S A. 1998.
Abstract
The serine-threonine kinase Akt is a downstream target of phosphoinositide 3-kinase (PI 3-kinase); it is activated by the phosphoinositide 3-phosphate-dependent kinases PDK1 and PDK2. Certain mutated forms of Akt induce oncogenic transformation in chicken embryo fibroblast cultures and hemangiosarcomas in young chickens. This ability to transform cells depends on localization of Akt at the plasma membrane and on the kinase activity of Akt. A transdominant negative form of Akt interferes with oncogenic transformation induced by the p3k oncogene, which codes for an activated form of PI 3-kinase. Akt is therefore an essential mediator of p3k-induced oncogenicity.
Figures
Figure 1
Schematic structures of Akt constructs. Group-specific antigen (Gag) sequence in v-Akt or myristylation signals are highlighted as black boxes. Functionally important amino acid residues in the PH and kinase domains are noted. The HA epitope tag is on the amino terminus of constructs 1 and 4–8; on all others, it is on the carboxyl terminus.
Figure 2
Morphology of CEF transfected with Akt constructs. (A) RCAS vector control. (B) c-Akt. (C) v-Akt. (D) Akt-E40K. (E) Akt-Myr. (F) Akt-K179M. (G and H) Phase-contrast micrographs of CEFs transfected with Akt-Myr (G) or RCAS vector (H).
Figure 3
Subcellular localization of the HA-tagged Akt proteins in CEF. (A) RCAS vector control. (B) c-Akt. (C) v-Akt. (D) Akt-E40K. (E) Akt-Myr. (F) Akt-K179M.
Figure 4
Expression and in vitro kinase activity of Akt proteins. (A and C) Lysates of CEF stably transfected with HA-tagged Akt were probed with anti-HA antibody in Western blots. (B and D) In vitro immune complex kinase assay of the HA-tagged Akt constructs with histone H2B as substrate.
Figure 5
Akt and cellular signaling. See text for details.
Similar articles
- Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase.
Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK. Chang HW, et al. Science. 1997 Jun 20;276(5320):1848-50. doi: 10.1126/science.276.5320.1848. Science. 1997. PMID: 9188528 - A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.
Aoki M, Blazek E, Vogt PK. Aoki M, et al. Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):136-41. doi: 10.1073/pnas.98.1.136. Proc Natl Acad Sci U S A. 2001. PMID: 11134523 Free PMC article. - Inhibition of protein synthesis by Y box-binding protein 1 blocks oncogenic cell transformation.
Bader AG, Vogt PK. Bader AG, et al. Mol Cell Biol. 2005 Mar;25(6):2095-106. doi: 10.1128/MCB.25.6.2095-2106.2005. Mol Cell Biol. 2005. PMID: 15743808 Free PMC article. - Molecular targeting: PI3 kinase pathway.
Dancey JE. Dancey JE. Ann Oncol. 2004;15 Suppl 4:iv233-9. doi: 10.1093/annonc/mdh932. Ann Oncol. 2004. PMID: 15477314 Review. No abstract available. - Kinase phosphorylation: Keeping it all in the family.
Peterson RT, Schreiber SL. Peterson RT, et al. Curr Biol. 1999 Jul 15;9(14):R521-4. doi: 10.1016/s0960-9822(99)80326-1. Curr Biol. 1999. PMID: 10421571 Review.
Cited by
- Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation.
Craven GB, Chu H, Sun JD, Carelli JD, Coyne B, Chen H, Chen Y, Ma X, Das S, Kong W, Zajdlik AD, Yang KS, Reisberg SH, Thompson PA, Lipford JR, Taunton J. Craven GB, et al. Nature. 2024 Nov 6. doi: 10.1038/s41586-024-08176-4. Online ahead of print. Nature. 2024. PMID: 39506119 - Potential anti-tumor effects of Solenopsis invicta venom.
Mo Y, Shi Q, Qi G, Chen K. Mo Y, et al. Front Immunol. 2023 May 22;14:1200659. doi: 10.3389/fimmu.2023.1200659. eCollection 2023. Front Immunol. 2023. PMID: 37283754 Free PMC article. No abstract available. - Actuation of single downstream nodes in growth factor network steers immune cell migration.
Pal DS, Banerjee T, Lin Y, de Trogoff F, Borleis J, Iglesias PA, Devreotes PN. Pal DS, et al. Dev Cell. 2023 Jul 10;58(13):1170-1188.e7. doi: 10.1016/j.devcel.2023.04.019. Epub 2023 May 22. Dev Cell. 2023. PMID: 37220748 Free PMC article. - Emerging RAS-directed therapies for cancer.
Conroy M, Cowzer D, Kolch W, Duffy AG. Conroy M, et al. Cancer Drug Resist. 2021 Apr 8;4(3):543-558. doi: 10.20517/cdr.2021.07. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582302 Free PMC article. Review. - Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.
Wang Y, He J, Xu M, Xue Q, Zhu C, Liu J, Zhang Y, Shi W. Wang Y, et al. Front Oncol. 2022 Feb 8;12:815654. doi: 10.3389/fonc.2022.815654. eCollection 2022. Front Oncol. 2022. PMID: 35211406 Free PMC article. Review.
References
- Chang H W, Aoki M, Fruman D, Auger K R, Bellacosa A, Tsichlis P N, Cantley L C, Roberts T M, Vogt P K. Science. 1997;276:1848–1850. - PubMed
- Toker A, Cantley L C. Nature (London) 1997;387:673–676. - PubMed
- Rodriguez-Viciana P, Warne P H, Dhand R, Vanhaesebroeck B, Gout I, Fry M J, Waterfield M D, Downward J. Nature (London) 1994;370:527–532. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous